A Double-Blind, Randomized, Prospective Study to Evaluate Adjunctive Risperidone Versus Adjunctive Placebo in Generalized Anxiety Disorder Sub-Optimally Responsive to Standard Psychotropic Therapy.

Trial Profile

A Double-Blind, Randomized, Prospective Study to Evaluate Adjunctive Risperidone Versus Adjunctive Placebo in Generalized Anxiety Disorder Sub-Optimally Responsive to Standard Psychotropic Therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 May 2010

At a glance

  • Drugs Risperidone (Primary)
  • Indications Generalised anxiety disorder
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 05 May 2009 Actual patient number (301) and actual end date (1 Jun 2005) added as reported by ClinicalTrials.gov.
    • 25 Oct 2007 Status changed from in progress to completed.
    • 09 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top